Cancer patients are at an increased risk of developing complications after a common heart procedure, reports a new study. The findings of the study are published in the European Heart Journal.
Research led by Keele University suggests that patients with cancer who undergo a common heart procedure have worse short-term clinical outcomes compared to non-cancer patients, in the largest study undertaken to date.
Percutaneous Coronary Intervention Lowers Risk of Heart Disease
Treating left main coronary artery disease with percutaneous coronary intervention lowers the risk of severe cardiovascular events after weeks of surgery.
Advertisement
‘Cancer patients are more at risk of complications following a common heart procedure known as percutaneous coronary intervention (PCI), reveals a new study.’
Tweet it Now
The study looked at 6.6 million hospital admissions in the USA over an 11-year period, in which the admitted patient underwent a percutaneous coronary intervention (PCI) procedure.
PCI is the most common interventional treatment undertaken in patients with coronary heart disease and is a procedure in which a stent is used to open up narrowed or blocked blood vessels in the heart, both as a planned procedure or in the emergency heart attack setting.
![Cancer Pain]( "Cancer Pain")
Approximately 10% of the patients who underwent a PCI procedure during the 11-year period analyzed had either a current or historical cancer diagnosis.
The study specifically looked at the impact on patients with a diagnosis of prostate, breast, colon or lung cancer, as these were the most prevalent in the dataset.
The study found that patients with a current diagnosis of lung cancer were three times more likely to die in hospital following a PCI procedure, compared to patients with no cancer. Colon cancer had the greatest association with major bleeding complications post-PCI, with a threefold increase compared to patients with no cancer. Patients with metastatic cancer, irrespective of cancer type, were found to have poorer outcomes following a PCI and were at increased risk of dying in the hospital, and suffering PCI complications, including major bleeding events.
Professor Mamas Mamas, Professor of Cardiology at Keele University who led the study commented:
"Our research found that a concurrent cancer diagnosis during these procedures is not uncommon, and it has an important impact on the clinical outcomes of these procedures, depending on the type of cancer, the presence of metastases, and whether the diagnosis is historical or current.
"This research is important because there is limited data regarding outcomes of patients undergoing PCI with a current or historical diagnosis of cancer. Such patients are often excluded from randomized controlled trials, and cancer history is not captured in national PCI registries. Clinicians are often unsure what the risks of these procedures are in these patients, and how best the procedures should be undertaken."
Dr. Jessica Potts, Research Associate at Keele University and co-author of the study, commented:
"Our recommendation is that treatment of patients with a cancer diagnosis should be individualized, recognizing that cancer is associated with a higher risk of complications, and should involve a close collaboration between cardiologists and oncologists."
Source: Eurekalert
Advertisement
Approximately 10% of the patients who underwent a PCI procedure during the 11-year period analyzed had either a current or historical cancer diagnosis.
The study specifically looked at the impact on patients with a diagnosis of prostate, breast, colon or lung cancer, as these were the most prevalent in the dataset.
The study found that patients with a current diagnosis of lung cancer were three times more likely to die in hospital following a PCI procedure, compared to patients with no cancer. Colon cancer had the greatest association with major bleeding complications post-PCI, with a threefold increase compared to patients with no cancer. Patients with metastatic cancer, irrespective of cancer type, were found to have poorer outcomes following a PCI and were at increased risk of dying in the hospital, and suffering PCI complications, including major bleeding events.
Professor Mamas Mamas, Professor of Cardiology at Keele University who led the study commented:
"Our research found that a concurrent cancer diagnosis during these procedures is not uncommon, and it has an important impact on the clinical outcomes of these procedures, depending on the type of cancer, the presence of metastases, and whether the diagnosis is historical or current.
"This research is important because there is limited data regarding outcomes of patients undergoing PCI with a current or historical diagnosis of cancer. Such patients are often excluded from randomized controlled trials, and cancer history is not captured in national PCI registries. Clinicians are often unsure what the risks of these procedures are in these patients, and how best the procedures should be undertaken."
Dr. Jessica Potts, Research Associate at Keele University and co-author of the study, commented:
"Our recommendation is that treatment of patients with a cancer diagnosis should be individualized, recognizing that cancer is associated with a higher risk of complications, and should involve a close collaboration between cardiologists and oncologists."
Source: Eurekalert
Surprising Trends Found in Cause of Long-Term Death After Percutaneous Coronary Intervention
More people with known coronary heart disease die because of other conditions like cancer, lung and neurological diseases, rather than heart disease as compared to 20 years ago, reveals a Mayo Study.
Advertisement
Rapid Percutaneous Coronary Intervention Crucial for the Survival of Heart Patients
Experts call for immediate action to reduce time to restoring blood flow in heart attack patients.
Advertisement
Recommended Reading
Latest Cancer News
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.
New combination of medications trametinib and entinostat were found to decrease lung cancer in mice.
Combination treatment with TALZENNA and XTANDI was found to benefit prostate cancer patients, revealed study.
In leukemia patients, reduced amounts of dietary vitamin A is associated with a higher risk and severity of pancreatitis.
